Navigation Links
Conseco Reaches Settlement of Multistate Market Conduct Examination
Date:5/7/2008

Agrees to $2.3 million fine

CARMEL, Ind., May 7 /PRNewswire-FirstCall/ -- Conseco, Inc. (NYSE: CNO) today announced a settlement among state insurance regulators and two of its insurance subsidiaries: Conseco Senior Health Insurance (CSHI) Company and Bankers Life and Casualty Company. The settlement concludes a multistate market conduct examination led by Pennsylvania, Illinois, Indiana, Texas and Florida related to long-term care claims practices and procedures, complaint handling, and sales and marketing practices.

Under the agreement:

-- Conseco will pay a fine of up to $2.3 million, with an additional $10

million in the event Conseco fails to meet the process improvement

benchmarks over the next two-and-a-half years.

-- Conseco will review certain claims from 2005-2007 and provide up to $4

million of remediation.

-- Conseco will implement a detailed process improvement plan designed to

achieve performance standards for the timely processing of claims and

complaints and other processes, as part of an improvement program

undertaken by the company in 2007. Under that program, Conseco is

moving several long-term care back-office functions to the Long-Term

Care Group, Inc. to better manage the CSHI business and improve

customer service, and Conseco is investing $26 million on systems

enhancements and business process improvements over the next

two-and-a-half years. The plan will be monitored by the lead states.

"Conseco encouraged and fully supported this exam, especially in light of industry policymakers' focus on senior marketplace issues relating to long-term care and spiraling healthcare costs," said Conseco CEO Jim Prieur. "As we expected, after an extensive review the examiners did not find that Conseco had engaged in a practice of improper claims denials."

"Conseco is committed to meeting the standards set forth in the forward-looking settlement to steadily improve our company," said Prieur. "We've been diligently working toward best-in-class service through the process improvement and enhancement program we implemented in 2007, and are already seeing meaningful results in claims and complaint handling."

"The conclusion of the multistate exam, the findings and the settlement are a positive step for not only our company but for the long-term care industry as a whole," Prieur said. "Private payer long-term care is extremely important, because our nation faces a huge demographic challenge. It is in the best interests of policyholders and taxpayers that the industry and regulators work together to find solutions to preserve the public's faith in long-term care insurance."

Conseco, Inc.'s insurance companies help protect working American families and seniors from financial adversity: Medicare supplement, long-term care, cancer, heart/stroke and accident policies protect people against major unplanned expenses; annuities and life insurance products help people plan for their financial futures. For more information, visit Conseco's web site at http://www.conseco.com/ .


'/>"/>
SOURCE Conseco, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Conseco Sets Earnings Release Date
2. Bischof Promoted to Vice President, Enterprise Risk Management at Conseco
3. Conseco Reports Fourth Quarter and Year-End Results
4. Conseco Files 10-K and Sets Earnings Release Date
5. Conseco Reports Preliminary Fourth Quarter and Year-End Results
6. Conseco Declines Partnerships Request for Board Seats; Review of Strategic Alternatives Underway
7. Conseco Files to Formally Extend Due Date for Annual Report on Form 10-K to March 17 and Reschedules Earnings Release and Investor Call
8. Hacker Joins Conseco as Senior Vice President and Treasurer
9. Tongson Joins Conseco as Senior Vice President, Corporate Actuarial
10. Conseco to Implement Systems and Operational Solution From Long Term Care Group
11. Conseco Reports Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: